Asher Biotherapeutics, Inc.

Henry C Nguyen

Yik Andy Yeung

Ivana Djuretic

David Y Liu

Renee L Greer

Byong Kang

Wei Chen

Sherman Michael Chin

Kelly Dare Moynihan

Irene Ni

Danielle C Pappas

Terrence Park

Paul Bessette

The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.

IL-21 polypeptides and targeted constructs

Provided herein are anti-CD8 antigen binding molecules and fusion polypeptides comprising the CD8 antigen binding molecules for selectively modulating the function of CD8+ T cells over other immune cells. In addition, the present disclosure also provides polynucleotides encoding the disclosed antigen binding molecules and fusion polypeptides, and vectors and host cells comprising such polynucleotides. The present disclosure further provides methods for producing the antigen binding molecules and fusion polypeptides, pharmaceutical compositions comprising the same, and uses thereof.

Fusions with CD8 antigen binding molecules for modulating immune cell function

Growing community of inventors

San Francisco, CA, United States of America

Henry C Nguyen